IP Library Granted Patent US 8,329,981
Granted Patent B2
US 8,329,981 · App. 13/081,035 · Granted Dec 11, 2012

Genetically modified non-human mammals and cells

Assignee: Crescendo Biologics Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,329,981
App. No.
13/081,035
Granted
Dec 11, 2012
Kind
B2
Abstract

A genetically modified mouse characterized in that it does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region locus polypeptide.

Claims (11)

1. A genetically modified mouse or mouse cell characterised in that it does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region locus polypeptide and in that one or more endogenous Ig H Variable region, one or more endogenous Ig H D segment, and one or more endogenous Ig H J segment nucleic acid sequences are present.

2. A genetically modified mouse or mouse cell according to claim 1 characterised in that all the endogenous Ig H Variable region, D and J segment nucleic acid sequences are present.

3. A genetically modified mouse or mouse cell according to claim 1 characterised in that it does not comprise a nucleic acid sequence which itself encodes any immunoglobulin heavy chain constant region (IgH C) polypeptide.

4. A genetically modified mouse or mouse cell according to claim 1 characterised in that all immunoglobulin heavy chain constant region gene sequences are absent or partially absent from the genome.

5. A genetically modified mouse or mouse cell according to claim 1 characterised in that it is obtainable or obtained by targeted deletion of essentially all endogenous IgH C gene sequences.

6. A genetically modified mouse or mouse cell according to claim 1 characterised in that it is obtainable or obtained by Cre loxP recombination.

7. A genetically modified mouse or mouse cell according to claim 1 characterised in that at least part of at least one IgH C gene enhancer sequence is present.

8. A genetically modified mouse or mouse cell according to claim 1 characterised in that a non-endogenous site-specific recombination sequence is present within the genome.

9. A genetically modified mouse or mouse cell according to claim 1 characterised in that all eight endogenous IgH C genes μ, δ, γ3, γ1, γ2a, γ2b, ε and α are absent or partially absent.

10. A genetically modified mouse cell according to claim 1 characterised in that it is an embryonic stem cell.

11. A genetically modified mouse or mouse cell derived from a genetically modified mouse or mouse cell of claim 1 .

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Aug 23, 2024
From: KREOS CAPITAL VII (UK) LIMITED
To: CRESCENDO BIOLOGICS LIMITED
Reel/Frame 068383/0031 →
SECURITY INTEREST Recorded Jul 21, 2023
From: CRESCENDO BIOLOGICS LIMITED
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 064342/0410 →
CONFIRMATORY ASSIGNMENT Recorded Apr 15, 2011
From: BABRAHAM INSTITUTE
To: TRANSLOCUS LIMITED
Reel/Frame 026133/0121 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2011
From: BRUGGEMANN, MARIANNE
To: BABRAHAM INSTITUTE
Reel/Frame 026133/0223 →
CHANGE OF NAME Recorded Apr 15, 2011
From: TRANSLOCUS LIMITED
To: CRESCENDO BIOLOGICS LIMITED
Reel/Frame 026133/0330 →
Priority Claims (1)
GB 0304374.2 · Feb 26, 2003 · national
Continuity (2)
Continuation 10547066
Related Publication 20110277047A1 · Nov 10, 2011